<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04556214</url>
  </required_header>
  <id_info>
    <org_study_id>TESLA trial</org_study_id>
    <nct_id>NCT04556214</nct_id>
  </id_info>
  <brief_title>Liver Transplantation for Non-Resectable Intrahepatic Cholangiocarcinoma: a Prospective Exploratory Trial (TESLA Trial)</brief_title>
  <official_title>Liver Transplantation for Non-Resectable Intrahepatic Cholangiocarcinoma: a Prospective Exploratory Trial (TESLA Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will investigate whether liver transplantation provides increased survival, low&#xD;
      side effects and good quality of life in patients with bile duct cancer where the tumor&#xD;
      cannot be removed by normal surgery. Analyzes of blood and tissue samples from the tumor will&#xD;
      be investigated to see if the analyzes can indicate who may have recurrence of the disease&#xD;
      after liver transplantation. Furthermore, the effect of chemotherapy on normal liver and&#xD;
      tumor tissues in the liver that are removed during transplantation will be investigated..&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2035</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2035</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From screening and until 36 months after inclusion</time_frame>
    <description>OS as assessed by quality of life questionnaire (QLQ-C30) patient reported outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival from time of relapse</measure>
    <time_frame>From time of relapse and until 36 months after inclusion</time_frame>
    <description>OS as assessed by QLQ-C30 patient reported outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>After liver transplantation and up 10 years after liver transplantation</time_frame>
    <description>CT-scan/MRI scan according to RECISTcriteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Start of new treatment/Change of strategy</measure>
    <time_frame>Immediately after liver transplatation to start of new treatment</time_frame>
    <description>Time to start of new treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to decrease in physical function and global health score</measure>
    <time_frame>Up to 10 years after liver transplantation</time_frame>
    <description>Quality of life measured by EORTC QLQ-C30),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver transplant Complication</measure>
    <time_frame>Up to 90 days after liver transplantation</time_frame>
    <description>Number of Clavien-Dindo grad 3-5 complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Developing other Malignancies</measure>
    <time_frame>Up to 10 years after liver transplantation</time_frame>
    <description>Diagnosis of other malignancies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival in relation to biological markers</measure>
    <time_frame>After Liver Transplant until 10 years after liver transplantation</time_frame>
    <description>CEA, CA 19-9 and Germline DNA analyses</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Intrahepatic Cholangiocarcinoma</condition>
  <arm_group>
    <arm_group_label>Liver Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients will be transplanted according to standard procedures by the institutional protocol. The transplantation procedure is initiated by an exploratory laparotomy with clinical assessment and frozen section of the lymphnodes in the hepatoduodenal ligament and along the common hepatic artery/coeliac axis. Evidence of disease dissemination to these regional lymph nodes will be an absolute contraindication to transplantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Liver Transplant</intervention_name>
    <description>Liver Transplant</description>
    <arm_group_label>Liver Transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically verified diagnosis of Intrahepatic Cholangiocarcinoma (iCCA)&#xD;
&#xD;
          -  First time iCCA or liver only recurrence after previous liver resection for iCCA&#xD;
&#xD;
          -  Disease deemed not eligible for liver resection based on tumor location or underlying&#xD;
             liver dysfunction&#xD;
&#xD;
          -  No vascular invasion, extrahepatic disease, or lymph node involvement detected on&#xD;
             imaging&#xD;
&#xD;
          -  No signs of extrahepatic metastatic disease according to positron emission computed&#xD;
             tomography (PET-CT) scan&#xD;
&#xD;
          -  Patient must be accepted for transplantation before progressive disease on&#xD;
             chemotherapy.&#xD;
&#xD;
          -  Twelve months or more time span from the diagnosis of iCCA and date of being listed&#xD;
             for liver transplantation&#xD;
&#xD;
          -  No signs of extrahepatic metastatic disease according to CT or magnetic resonance (MR)&#xD;
             scan within 4 weeks prior to the faculty meeting at the transplant unit&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  Good performance status, Eastern Cooperative Oncology Group (ECOG) 0 or 1&#xD;
&#xD;
          -  Signed informed consent and expected cooperation of the patients for the treatment and&#xD;
             follow up&#xD;
&#xD;
          -  Received at least 6 months of chemotherapy or locoregional therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major vascular involvement of the tumor&#xD;
&#xD;
          -  Perforation of the visceral peritoneum&#xD;
&#xD;
          -  Weight loss &gt;15% the last 6 months&#xD;
&#xD;
          -  Patient BMI &gt; 30&#xD;
&#xD;
          -  Other malignancies, except curatively treated more than 5 years ago without relapse&#xD;
&#xD;
          -  Known history of human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Prior history of solid organ or bone marrow transplantation&#xD;
&#xD;
          -  Substance abuse, medical, psychological, or social conditions that may interfere with&#xD;
             the patient's participation in the study or evaluation of the study results&#xD;
&#xD;
          -  Known hypersensitivity to rapamycin&#xD;
&#xD;
          -  Prior extrahepatic metastatic disease&#xD;
&#xD;
          -  Women who are pregnant or breast feeding&#xD;
&#xD;
          -  Any reason why, in the opinion of the investigator, the patient should not participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Svein Dueland, PhDMD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Svein Dueland, PhDMD</last_name>
    <phone>+4722934000</phone>
    <email>svedue@ous-hf.no</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0310</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Svein Dueland, MD</last_name>
      <phone>22934000</phone>
      <phone_ext>47</phone_ext>
      <email>svein.dueland@ous-hf.no</email>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 30, 2020</study_first_submitted>
  <study_first_submitted_qc>September 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2020</study_first_posted>
  <last_update_submitted>October 13, 2020</last_update_submitted>
  <last_update_submitted_qc>October 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Svein Dueland</investigator_full_name>
    <investigator_title>Senior consultant medical oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

